Status:
UNKNOWN
The Safety and Efficacy of TWP-101 in Patients With Advanced Solid Tumor
Lead Sponsor:
Shandong TheraWisdom Biopharma Co., Ltd.
Conditions:
Advanced Solid Tumor
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
This is a multi-center, phase Ia/Ib, open clinical study to evaluate the safety and efficacy of TWP-101 in patients with advanced solid tumor. This study consists of two parts (Part A and Part B). Par...
Eligibility Criteria
Inclusion
- Pathologically or cytologically confirmed advanced solid tumor that failed, couldn't tolerate or refused standard treatments;
- ECOG score 0 or 1;
- At least 1 measurable lesion according to RECIST 1.1
Exclusion
- Known hypersensitivity to any ingredient of TWP-101;
- Receiving any anti-cancer drugs within 4 weeks;
- History of serious systemic diseases;
- History of serious autoimmune diseases;
- Pregnancy or lactating women.
Key Trial Info
Start Date :
August 30 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT04871347
Start Date
August 30 2021
End Date
December 31 2023
Last Update
July 27 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China, 150001